Galderma Group N (GALD SW) stock market data APIs
CHF162.7035
4.29(2.6%)
as of December 16, 2025
Try our APIs with
free plan!
Galderma Group N Financial Data Overview
Price chart is built with
Anychart
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Prev. Close
162.7035
Open
166.9933
High
168.9323
Low
160.9178
52 wk Range
72.5788-170.1
Market Cap
38 199 M
P/E Ratio
127.6984
Shares Outstanding
235 M
Revenue
4 690 M
EPS
0.82
Dividends (Yield)
0.001
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galderma Group N (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galderma Group N data using free add-ons & libraries
Get Galderma Group N Fundamental Data
Galderma Group N Fundamental data includes:
- Net Revenue: 4 690 M
- EBITDA: 988 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-24
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galderma Group N News
New
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation ...
Is It Too Late to Consider Galderma After Its 61% Surge in 2025?
If you are wondering whether Galderma Group is still attractive after its big run, or if the easy money has already been made, you are not alone. That is exactly what this valuation deep dive will unp...
L’Oréal Doubles Stake in Swiss Skincare Company Galderma
Financial terms weren’t disclosed, but the package of about 24 million Galderma shares would be valued at $4.85 billion based on Friday’s closing price. Continue Reading
Evaluating Galderma Group (SWX:GALD) After a 60% Year-to-Date Rally and Strong Shareholder Returns
Galderma Group (SWX:GALD) has been quietly rewarding patient holders, with the stock up about 13% over the past month and roughly 60% year to date, outpacing many healthcare peers. See our latest ana...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
